ArchiveApril 2021

COVID blood spot study – where are we up to?

The first thing to say is a massive thank you to everyone that has been involved so far – both in raising the funds for this study and signing up to take part. We couldn’t have got this far without you. We have had a phenomenal response to this study. So far, in just over 4 months, we have recruited 320 people, and got hundreds of blood spots back. In the background, Nikki and her team have...

Pack your DMT tools for the long run!

Over the past year, I was privileged to counsel many people when starting an MS disease-modifying treatment (DMT), and reviewed even more pwMS whom had been on a DMT for a considerable amount of time. This has given me valuable insights in which drug-related characteristics matter in the long run, both literally and figuratively. First, there is no doubt about the fact that some drugs are more...

COVID Thursday Lunch

Benchmark of what we can hope when you get vaccinated…UK non-MS experience Impact of vaccination on SARS-CoV-2 cases in the community: a population-based study using the UK COVID-19 Infection SurveyPritchard, E., Matthews, P., Stoesser, N., Eyre, D., Gethings, O., Vitha, K.-D., Jones, J., House, T., VanSteenhouse, H., Bell, I., Bell, J., Newton, J., Farrar, J., Diamond, I., Rourke, E...

Early treatment is important to limit accumulation of disability

Iaffaldano P, Lucisano G, Butzkueven H, Hillert J, Hyde R, Koch-Henriksen N, Magyari M, Pellegrini F, Spelman T, Sørensen PS, Vukusic S, Trojano M. Early treatment delays long-term disability accrual in RRMS: Results from the BMSD network. Mult Scler. 2021 Apr 26:13524585211010128. doi: 10.1177/13524585211010128. Background: The optimal timing of treatment starts for achieving the best...

Happy dominos are the prettiest!

The prevalence of MS is not equally spread around the world, and is associated with latitude. Apart from some exceptions such as Sardinia, people living more closely to the equator are less likely to develop MS. Strikingly, when an individual moves before the age of 15 years old from for example Kenia (low MS prevalence) to the UK (medium MS prevalence), it will acquire the MS risk of his new...

Do you know your neurofilament level?

In my opinion, if the latter half of the 21st century in MS was defined by something it was the realization that neurofilament levels introduce clarity into individual disease courses that was not possible with clinical descriptors or MRI alone. The days of wandering what your MS is going to be like in the future may well be over as new tools such as neurofilaments become more readily available...

Snooze it or Lose it

ProfG has repeatedly said ensure your sleep health is good. I sadly am now on course for a 30% increase risk of dementia….Maybe that,s the problem ;-)..I guess time for some more snoozing and snoring and no more 2 am zooms. Sabia, S., Fayosse, A., Dumurgier, J. et al. Association of sleep duration in middle and old age with incidence of dementia. Nat Commun 12, 2289...

Natalizumab. Keeping you safe in the COVID-19 era.

ProfG asked do we give up the idea of IRT dosing for ocrelizumab? I suspect that eventually a trial will happen. Sadly however, I will have given up the will to live by then:-(. Why do this?. Simple…..to look at safety. If you continually deplete B cells there is an increased, albeit a small increase, in the risk of serious infections eventually happening. This is all well and...

How does cladribine work? Clad-COVID…More Good News for ChariotMS, but it’s not all good.

So more good news for ChariotMS. News has started to surface that you get COVID-19 responses in vaccinated individuals and if you do catch COVID-19, you do not seem to be worse than the general population. This is the message from the latest update from Merck. This is good news for ProfK, who is hoping to start recruitment for ChariotMS in June (yes, this year 2021!). However, I must say the...

Translate

Categories

Recent Posts

Recent Comments

Archives